Biohaven Pharma (BHVN) Misses Q2 EPS by 172c
Tweet
Share
E-mail
Get Alerts BHVN Hot Sheet
Join SI Premium – FREE
Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.50), $1.72 worse than the analyst estimate of ($1.78).
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- BMO Capital Starts Abercrombie & Fitch (anf) at Outperform
- BMO Capital Starts Carter's (CRI) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
